|
EDEMOFIN®
Reg. SAGARPA: Q-0021-017
DIURETIC
VETERINARY USE
INJECTABLE SOLUTION, MODERN AND POTENT DIURETIC AND SALURETIC
FORMULA:
Each ml contain: |
|
Acido 4-chloro N-furfuryl |
|
5-sulfamoilantranilic (Furosemida) |
50 mg |
Vehicle q.s. |
1 ml |
NDICATIONS:
Cattle: Mamary or vulvar edema post-partum, chronic or pathologic mamalian oedema in milk cows edema associated to heart insufficiency. Edema derived tumefactions in surgery wounds (extraneous objects extraction, caesarean).
Horses: Laminitis , myositis (myopathy), edema pre and post-partum, congestive local edema of diverse origin, preputial edema.
Dogs: Edema associated to heart insufficiency. Edema associated to cirrhosis and/or renal failure.
DOSE:
Cattle and horses: 5 – 10 ml (250 to 500 mg) each 12-24 hours.
Dogs: 1 – 2 ml (50 to 100 mg) each 24-48 hours.
These dosing schemes may be considered average and will be administered and/or repeated under veterinary supervision.
ROUTE OF ADMINISTRATION: Intramuscular and/or intravenous (SLOW), with slution at animal’s body temperature.
Note: Excessive dose may cause dehydration, electrolitic deficit state, and this conditions must be compensated, before of after diuretic treatment and under veterinary supervision.
WARNINGS:
Do not use in horses intended for human consumption until 48 hours after last dose.
Do not eat meat from treated animals until 48 hours after last dose.
Do not drink milk from treated animals until 48 hours after last treatment.
Keep in a dark and fresh place for its storing.
PRESENTATION: 10 ml vial
CONSULT VETERINARIAN
MEDICAL PRESCRIPTION IS NECESSARY FOR SALE
EDEMOFIN® is a diuretic of Henle haft, derived from monosulfamilantranylic acid. It diuretic potency puts it web above other diuretics and produces a higher chlorine excretion. It mechanism of action is not known exactly, but it has been observed that inhibits sodium resorption in ascending portion of Henle haft and proximal twisted tubes.
MECHANISM OF ACTION
Its mechanism of actions is not known exactly, but it has been observed that inhibits sodium resorption in ascending portion of Henle haft and proximal twisted tubes. Promotes chlorine and potassium ions excretion. The diuretic effect of EDEMOFIN® is independent of the acid basic balance of the patient.
Induces certain degree of vascular dilation and a light increase in glomerular filtration.
EDEMOFIN®.- is compatible with intravenous solutions and with amikacyn, cymetidin, kanamycin, tobramycin, verapamil; it is not compatible with acid solutions, dobutamine, gentamicyin, tetracycline, antihystamínics, alcaloids.
THERAPEUTIC INDICATIONS
DOGS
EDEMOFIN®. – Is indicated for therapy of congestive heart failure, togheter with oral supplementation of K vitamin. It is also used for lung edema, neuropathy, hipercalciury, cynury, uremia, hiperkalemia and as anti tension agent.
CATTLE
EDEMOFIN®.- Is indicated for udder post-partum edema and in cases of edema from different causes, including cardiovascular, parasitaries y nutritional.
HORSES
EDEMOFIN®. – Additionally to the above mentioned indications, it is used to reduce epistaxis called EIPH (exercise-induced pulmonary hemorrhage) in race horses.
FARMACOKINETICS
It is known that in dogs after IM administration bioavailability of 85-90%. Has a half life of 1-1.5 hours. The drug binds in 90-95% to plasmatic proteins.
It has been estimated that in cattle and horses half life is longer (3-4 hours) allowing an interval between doses of 24 hours.
EDEMOFIN®.- Is safe, its LD50 in dogs is more than 1000 mg/kg after IM administration and 300 mg/kg IV.
EDEMOFIN® must be used carefully in patienst with electrolytic alterations as well as hepatic function alterations.
|
